IBI-354 is under development for the treatment of solid tumors, breast cancer, ovarian cancer, endometrial cancer and colorectal cancer. The drug candidate is a recombinant anti-HER2 monoclonal ...
"The School aims to enhance the way we use technology in research, food security, microbiology, ecosystem biology, sustainability and many other related areas. The School is dedicated to providing the ...
Monstrilio summary Big move! Shanghai Pharmaceuticals introduces 6 blockbuster biological drugs, including PD-1 and adalimumab Keytruda combination therapy for gastric cancer achieves positive ...
INR:0354. junglee rummy apkpure️ Innovent's entry into the market of Adalimumab to challenge Humira coincides with AbbVie being subpoenaed for high pri ...